humanized

Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.

阿仑单,一种源性-CD52,在免疫耐受诱导方案中著,需要最少的免疫抑制维持药物.

Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.

为了降低鼠源引起的超敏反应,治疗性单克隆已由改型,源化发展到全。